Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis

This study has been terminated.
(Primary endpoint (heat shock proteins) cannot be analyzed with the described laboratory method as specified in the protocol.)
Sponsor:
Information provided by (Responsible Party):
Christoph Aufricht, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01353638
First received: May 5, 2011
Last updated: June 12, 2012
Last verified: June 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2012
  Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)